Martin Gotte obtained his M.S. degree in biology at the University of Munster, Germany in 1994. After studying the role of Rab GTPases and SNAREs in vesicular trafficking to the yeast vacuole in the laboratory of Dieter Gallwitz at the Max Planck Institute of Biophysical Chemistry in Gottingen, Germany, he obtained his Ph.D. degree in bBiochemistry from the University of Gottingen in 1997. From 1997 to 2000, he studied the role of cell surface heparan sulfate proteoglycans in inflammation, angiogenesis, and tumorigenesis in the laboratory of Merton Bernfield at the Department of Cell Biology of Bostons Harvard Medical School. From 2000 to 2003, he served as a Group Leader at the Institute of Physiological Chemistry and Pathobiochemistry at Munster University Hospital, Germany, studying syndecans, galactosyltransferase, proteoglycan endocytosis, and basement membrane proteoglycans. From 2001 to 2003, he has been Managing Director of the biotech company Protogeneia, Inc. In November 2003, he became a Faculty Member of the Department of Obstetrics and Gynecology of Munster University Hospital, where he continues his work on syndecans, dermatan sulfate proteoglycans, and the molecular mechanisms of angiogenesis in malignant diseases. Dr. Gotte is a Member of the German Society for Cell Biology, the New York Academy of Sciences, the Federation of European Biochemical Societies, and the International Union of Biochemistry and Molecular Biology. His Research has been funded by the German Research Council DFG, the NIH, the Max Planck Society, the German Academic Exchange Service and industry sources, and led to publications in a variety of peer-reviewed journals, including Annual Reviews in Biochemistry, Trends in Biochemical Sciences, Trends in Cell Biology, the FASEB Journal, the Journal of Biological Chemistry, and The Scientific World Journal.
Biography Updated on 27 March 2011